26,035 Shares in AtriCure, Inc. (NASDAQ:ATRC) Acquired by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 26,035 shares of the medical device company's stock, valued at approximately $796,000. AlphaCentric Advisors LLC owned about 0.05% of AtriCure as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ATRC. Assenagon Asset Management S.A. lifted its stake in shares of AtriCure by 151.6% in the third quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company's stock worth $6,425,000 after buying an additional 138,046 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in AtriCure by 31.5% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company's stock valued at $14,038,000 after acquiring an additional 119,929 shares during the last quarter. Champlain Investment Partners LLC raised its holdings in AtriCure by 4.3% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company's stock valued at $78,253,000 after acquiring an additional 115,813 shares during the last quarter. Two Sigma Advisers LP lifted its stake in AtriCure by 14.6% in the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company's stock worth $18,621,000 after purchasing an additional 84,700 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of AtriCure during the 3rd quarter worth approximately $1,991,000. Institutional investors and hedge funds own 99.11% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Piper Sandler increased their price target on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Oppenheimer raised their target price on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Needham & Company LLC reissued a "buy" rating and set a $51.00 price target on shares of AtriCure in a research report on Thursday, February 13th. JMP Securities reissued a "market outperform" rating and issued a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. Finally, Canaccord Genuity Group raised their price objective on shares of AtriCure from $61.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $51.56.

AtriCure Trading Up 0.4 %

Shares of ATRC traded up $0.15 during trading on Thursday, reaching $39.16. 483,372 shares of the company traded hands, compared to its average volume of 605,581. The stock has a 50-day simple moving average of $36.23 and a 200-day simple moving average of $31.85. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The stock has a market cap of $1.91 billion, a PE ratio of -41.22 and a beta of 1.46.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.